NCT01573312View on ClinicalTrials.gov

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 24, 2012

Primary Completion Date

January 2, 2014

Study Completion Date

January 2, 2014

Conditions
Influenza
Interventions
DRUG

ASO3 Adjuvant

3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.

BIOLOGICAL

Influenza A/H5N1 Vaccine

3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.

Trial Locations (1)

37232-2573

Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01573312 - H5N1 Vaccination With and Without AS03: Systems Biology Analysis | Biotech Hunter | Biotech Hunter